Enlivex Launches Cost Reduction Plan To Prioritize Phase 2b Allocetra Knee Osteoarthritis Trial, Topline Data Expected By Mid-2027

• Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trial
• Workforce reduced by approximately 60%; management and CEO salaries reduced
• Plan designed to substantially reduce cash burn
• Topline Phase 2b six-month endpoint data expected by mid-2027

Nes-Ziona, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) --  Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a cost reduction plan, effective immediately, designed to substantially reduce the Company's cash burn and focus its resources on the execution of its Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The Company expects to report topline six-month data from the trial by mid-2027.

The Company’s plan includes the following measures:

• Wind-down of non-clinical R&D: The Company is winding down, effective immediately, all research and development activities not related to the Phase 2b clinical trial.
• Focus on clinical execution: The Company's resources will be dedicated to the execution of the Phase 2b trial and related activities.
• Workforce reduction: The Company is reducing its workforce by approximately 60%.
• Management compensation reduction: Salaries for the Company's management team will be reduced by 20%, and the Chief Executive Officer’s will be reduced by 40%.